ClinicalTrials.gg
CompletedNCT05142514Updated Nov 17, 2026

Safety and Immunogenicity of Recombinant Protein RBD Fusion Dimer Vaccine Against the Virus That Cause COVID-19, Known as Severe Acute Respiratoy Syndrome Coronavirus 2 (SARS-CoV-2)

A Phase 2 interventional study of COVID-19 Vaccine HIPRA and Cominarty (Pfizer-BioNtech) in SARS-CoV-2 Infection, sponsored by Hipra Scientific, S.L.U. Completed at 1 site in Vietnam. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Hipra Scientific, S.L.U · Phase 2, Interventional, and Prevention

How we know

Updated Nov 17, 2026Primary completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
629
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in COVID-19 with a site in Vietnam — 4 open to participants now, 4 under way, 2 of them phase 3. COVID-19 · Vietnam.

Enrollment
10th of 23
629 · median 573
Started
2021
with 12 others
Phase 2
5 of 30
none open now
Registered
20th of 30
by date
Lead sponsor
1 of 30
Hipra Scientific, S.L.U

Among the 30 studies in COVID-19 with a site in Vietnam, this one is the 10th largest by enrollment of the 23 interventional ones that give a count, is one of 13 that started in 2021, is one of 5 in phase 2, and was the 20th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 30 studies in COVID-19 with a site in Vietnam are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Vietnam have not opened yet or have stopped. Only those recruiting at a site in Vietnam →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in COVID-19 with a site in Vietnam, or all of them as a file.
02

Study summary

This is a Phase IIb, randomized, controlled, observer-blinded, clinical trial to evaluate safety and immunogenicity of COVID-19 Vaccine HIPRA in adult healthy volunteers in Vietnam

Read the detailed description

The study population includes 256 healthy adults aged 18-60 which will be randomized in a ratio 1:1 test:commercial vaccine. Each participant will receive 2 immunisations separated by 21 days and will be followed for 24 weeks after the second dose.

03

Conditions studied

  • SARS-CoV-2 Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults males or females between 18-60 years of age at the day of screening.
  • Willing and able to comply with scheduled visits, laboratory test, complete diaries and other study procedures.
  • 18 to 40 Kg/m2 at screening.
  • COVID19 negative quick test or PCR test and negative serum IgG binding antibody response to the SARS-CoV-2 S glycoprotein at screening or prior the first vaccination. If an enrolled subject has neutralizing antibodies at baseline, he or she will be excluded from final analysis.
  • Willing to avoid all other vaccines within 4 weeks before and after each injection. Seasonal influenza vaccination is allowed if it is received at least 14 days before or after the vaccination.
  • Women of must have a negative pregnancy test in urine before the inclusion of the study and prior to each vaccination.
  • If female of childbearing potential, willing to use highly effective methods or have practiced sexual abstinence from the screening visit until 8 weeks after the last injection.
  • If male and not sterilized, willing to avoid impregnating female partners from screening until 8 weeks after last injection.
  • Willing and able to provide written prior the initiation of any study procedures.

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating or intending to become pregnant or plans to breastfeed during the study.
  • Positive pregnancy test at screening or prior to each vaccination.
  • Any medical disease (acute, subacute, intermittent or chronic) or condition with grade 2 or above that in the opinion of the investigator compromise the volunteer's safety, preclude vaccination or compromise interpretation of the results.
  • History of serious psychiatric condition likely to affect participation in the study.
  • History of respiratory disease (e.g., (COPD) and asthma) requiring any daily medications currently or any treatment of respiratory disease exacerbations (e.g., asthma exacerbation) in the last 5 years.
  • History of significant cardiovascular disease including hypertension (e.g., congestive heart failure, cardiomyopathy, ischemic heart disease) or history of myocarditis or pericarditis as an adult.
  • History of neurological or neurodevelopmental conditions (e.g., migraines, epilepsy, stroke, seizures in the last 3 years, encephalopathy, focal neurologic deficits, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis).
  • Ongoing or recent diagnosis of malignancy in the last five years excluding basal cell and squamous cell carcinoma of the skin, which are allowed.
  • Any confirmed or suspected or immunodeficient state, including infection; asplenia; recurrent severe infections.
  • Any or immunodeficiency disease/condition (iatrogenic or congenital).
  • Acute illness within 72 hours prior each vaccination that in the opinion of the investigator may interfere the evaluation of safety parameters.
  • Usage of any drug ≤ 90 days prior to study entry or plan to participate in another research involving an investigational product (drug/biologic/device) within 12 months after the first study vaccination.
  • History of or severe allergic reaction including anaphylaxis, generalized urticarial, angioedema and other significant reactions related to food, drugs, vaccines or pharmaceutical agents.
  • History of allergic disease or reactions likely to be exacerbated by any component of the COVID-19 vaccine HIPRA
  • Use of any immunosuppressant, , or other immune-modifying drugs within 2 months prior to first study vaccination; or anticipation of the need for immunosuppressive treatment within 6 months after last vaccination.
  • Received immunoglobulin, blood-derived products, or other immunosuppressant drugs within 90 days prior to first study vaccination.
  • Known disturbance of coagulation (iatrogenic or congenital) or blood dyscrasias.
  • Known bleeding disorder (e.g. factor deficiency, coagulopathy or disorder), or prior history of significant bleeding or bruising following IM injections or venepuncture.
  • Chronic liver disease
  • Positive test for HIV types 1 or 2 infection, surface antigen (HBsAg), or virus antibodies (HCV Abs) at screening
  • Suspected or known current alcohol abuse or any other substances abuse (except tobacco).
  • History of COVID-19 infection.
  • Receipt of medications intended to prevent COVID-19.
  • Ever received an experimental vaccine against COVID-19.
  • Close contact of anyone known to have SARS-CoV-2 infection within 15 days prior to screening visit.
  • Being directly involved in the conduct of the study
  • Any condition and/or laboratory finding that at the investigator consideration would interfere with the study or put at risk the participant.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Single group
Masking
Double (Participant, Investigator)
Enrollment
629 participants (actual)

Study arms

  • Experimental
    COVID-19 Vaccine HIPRA

    Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart.

    Biological: COVID-19 Vaccine HIPRA

  • Active comparator
    Commercial COVID-19 Vaccine

    Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart

    Biological: Cominarty (Pfizer-BioNtech)

Interventions

  • BiologicalHIPRA COVID-19 vaccineStudies of HIPRA COVID-19 vaccineHIPRA COVID-19 vaccine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Subjects will receive 2 injections of COVID-19 vaccine HIPRA administered 21 days apart

  • BiologicalCominarty (Pfizer-BioNtech)

    Subjects will receive 2 injections of Cominarty administered 21 days apart

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers

    Number and percentage of solicited local and systemic reactogenicity adverse events for 7 days following each vaccination.

    Time frame: 7 days

  2. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers

    Number and percentage of unsolicited local and systemic reactogenicity adverse events for 28 days following each vaccination.

    Time frame: 28 days

  3. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers

    Change from baseline in safety laboratory parameters at 7 days following each vaccination.

    Time frame: 7 days

  4. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers

    Number and percentage of serious adverse events throughout the study duration.

    Time frame: 30 weeks

  5. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers

    Number and percentage of adverse events of special interest (AESI) throughout the study duration.

    Time frame: 30 weeks

  6. Safety and tolerability of COVID-19 HIPRA vaccine in healthy adult volunteers

    Number and percentage of medically attended adverse events (MAAE) related to study vaccine throughout the study duration.

    Time frame: 30 weeks

Secondary outcomes

  1. Immunogenicity

    Neutralization titer for each individual sample and GMT for group comparison at Day 21 and 35.

    Time frame: Day 21 and 35.

  2. Immunogenicity

    IC50 of beta and delta variants.

    Time frame: Day 21 and 35.

  3. Immunogenicity

    Geometric mean fold rise (GMFR) in neutralizing antibodies titers from baseline at Day 21 and 35.

    Time frame: Day 21 and 35.

  4. Immunogenicity at long-term

    Neutralization titer for each individual sample and GMT for group comparison at 24 and 48 weeks after the second dose.

    Time frame: 24 and 48 weeks after the second dose

  5. Immunogenicity at long-term

    IC50 of beta and delta variants.

    Time frame: 24 weeks after the second dose

  6. Immunogenicity at long-term

    GMFR in neutralizing antibodies titers from baseline at 24 weeks after the second dose.

    Time frame: 24 weeks after the second dose

  7. Immunogenicity to the SARS-CoV-2 spike glycoprotein

    Total binding antibody titer and GMT for group comparison at Day 21 and 35.

    Time frame: Day 21 and 35

  8. Immunogenicity to the SARS-CoV-2 spike glycoprotein

    GMFR in total binding antibodies titer from baseline at Day 21 and 35.

    Time frame: Day 21 and 35

  9. Immunogenicity to the SARS-CoV-2 spike glycoprotein at long-term

    Total Binding antibody titer and GMT for group comparison at 24 weeks after the second dose.

    Time frame: 24 weeks after the second dose

  10. Immunogenicity to the SARS-CoV-2 spike glycoprotein at long-term

    GMFR in total binding antibodies titer from baseline at 24 weeks after the second dose.

    Time frame: 24 weeks after the second dose

  11. Immunogenicity to the SARS-CoV-2 spike glycoprotein

    Percentage of subjects who seroconverted defined as a ≥4-fold change in total binding antibody titer from baseline at Day 21 and 35.

    Time frame: Day 21 and 35.

Other outcomes

  1. Number of participants with symptomatic SARS-CoV-2 infections in participants without evidence of infection before COVID-19 HIPRA vaccination.

    Number and percentage of subjects with symptomatic SARS-CoV-2 infections according to COVID-19 infection criteria.

    Time frame: 30 weeks

  2. Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.

    Number and percentage of COVID-19 severe infections throughout the study duration.

    Time frame: 30 weeks

  3. Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.

    Number and percentage of hospital admissions associated with COVID-19 throughout the study duration.

    Time frame: 30 weeks

  4. Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.

    Number and percentage of intensive care unit (ICU) admissions associated with COVID-19 throughout the study duration.

    Time frame: 30 weeks

  5. Number of COVID-19 severe infections after receiving COVID-19 HIPRA vaccine.

    Number and percentage of deaths associated with COVID-19 throughout the study duration.

    Time frame: 30 weeks

07

Study locations

1 site
  • National Institute of Hygiene and Epidemiology
    Hanoi, Vietnam
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2021 to primary completion in May 2022, 5 months.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 5 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

Primary completion moved once since we started tracking on Sep 25, 2026: Dec 2021 → May 2022, on Nov 17, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2021
First posted
Dec 2, 2021
StartActual
Nov 11, 2021
Primary completionActual
May 6, 2022was Dec 2021
CompletionActual
May 6, 2022
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 27, 2021→May 6, 2022
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Dec 27, 2021→May 6, 2022
    + 3 other changes: identifiers, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05142514
Lead sponsor
Hipra Scientific, S.L.U
Collaborators
Laboratorios Hipra, S.A., National Institute of Hygiene and Epidemiology, Vietnam
Responsible party
Sponsor
First posted
Dec 2, 2021
Start date
Nov 11, 2021
Primary completion
May 6, 2022
Completion
May 6, 2022
Last update
Nov 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HIPRA COVID-19 vaccine

Start the discussion